Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study

PLoS One. 2016 Jan 25;11(1):e0147804. doi: 10.1371/journal.pone.0147804. eCollection 2016.

Abstract

Background and aims: Early detection of fibrosis is important in identifying individuals at risk for advanced liver disease in non-alcoholic fatty liver disease (NAFLD). We tested whether second-harmonic generation (SHG) and coherent anti-Stokes Raman scattering (CARS) microscopy, detecting fibrillar collagen and fat in a label-free manner, might allow automated and sensitive quantification of early fibrosis in NAFLD.

Methods: We analyzed 32 surgical biopsies from patients covering histological fibrosis stages 0-4, using multimodal label-free microscopy. Native samples were visualized by SHG and CARS imaging for detecting fibrillar collagen and fat. Furthermore, we developed a method for quantitative assessment of early fibrosis using automated analysis of SHG signals.

Results: We found that the SHG mean signal intensity correlated well with fibrosis stage and the mean CARS signal intensity with liver fat. Little overlap in SHG signal intensities between fibrosis stages 0 and 1 was observed. A specific fibrillar SHG signal was detected in the liver parenchyma outside portal areas in all samples histologically classified as having no fibrosis. This signal correlated with immunohistochemical location of fibrillar collagens I and III.

Conclusions: This study demonstrates that label-free SHG imaging detects fibrillar collagen deposition in NAFLD more sensitively than routine histological staging and enables observer-independent quantification of early fibrosis in NAFLD with continuous grading.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Humans
  • Liver Cirrhosis / pathology*
  • Male
  • Microscopy, Fluorescence
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / pathology*

Grants and funding

This work was financially supported by the Academy of Finland (EI grants 131489, 263841, 272130; TP grant 251314; S-MK grant 259872, HYJ), European Union/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking (European Medical Information Framework EMIF grant no. 115372, HYJ), the Sigrid Juselius (EI, TP, HYJ), Special governmental subsidy for health sciences research (EVO, Helsinki University Central Hospital grant, HYJ) and the Novo Nordisk Foundation (HYJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.